- Home
- TPVG vs TSHA Comparison
TPVG vs TSHA Comparison
Compare TPVG & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPVG
- TSHA
- Stock Information
- Founded
- TPVG 2013
- TSHA 2019
- Country
- TPVG United States
- TSHA United States
- Employees
- TPVG N/A
- TSHA N/A
- Industry
- TPVG Other Consumer Services
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- TPVG Consumer Discretionary
- TSHA Health Care
- Exchange
- TPVG Nasdaq
- TSHA Nasdaq
- Market Cap
- TPVG 296.2M
- TSHA 334.1M
- IPO Year
- TPVG N/A
- TSHA 2020
- Fundamental
- Price
- TPVG $7.06
- TSHA $1.76
- Analyst Decision
- TPVG Hold
- TSHA Strong Buy
- Analyst Count
- TPVG 5
- TSHA 8
- Target Price
- TPVG $7.50
- TSHA $6.63
- AVG Volume (30 Days)
- TPVG 336.5K
- TSHA 1.6M
- Earning Date
- TPVG 03-05-2025
- TSHA 02-26-2025
- Dividend Yield
- TPVG 17.01%
- TSHA N/A
- EPS Growth
- TPVG N/A
- TSHA N/A
- EPS
- TPVG 0.82
- TSHA N/A
- Revenue
- TPVG $108,208,000.00
- TSHA $8,333,000.00
- Revenue This Year
- TPVG N/A
- TSHA N/A
- Revenue Next Year
- TPVG $0.42
- TSHA N/A
- P/E Ratio
- TPVG $8.59
- TSHA N/A
- Revenue Growth
- TPVG N/A
- TSHA N/A
- 52 Week Low
- TPVG $6.44
- TSHA $1.19
- 52 Week High
- TPVG $9.73
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- TPVG 30.36
- TSHA 60.47
- Support Level
- TPVG $7.25
- TSHA $1.69
- Resistance Level
- TPVG $7.50
- TSHA $1.79
- Average True Range (ATR)
- TPVG 0.20
- TSHA 0.11
- MACD
- TPVG -0.09
- TSHA 0.01
- Stochastic Oscillator
- TPVG 3.01
- TSHA 69.84
About TPVG TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.